Characterization of Antibody-Drug Conjugates as Cancer Therapeutics
Systemic toxicity is one of the major problems with cancer therapeutics, resulting in limited dosing and patient suffering. Targeted therapies attempt to prevent systemic toxicity by having the therapeutic only act on cancerous cells. One type of targeted therapy is antibody-drug conjugates (ADCs), which consist of an antibody for targeted delivery covalently conjugated to a chemotherapeutic drug. The antibody component specifically binds to receptors over-expressed in cancerous cells. Once internalized, the drug component of an ADC is cleaved from the rest of the ADC and acts as a chemotherapeutic. Kinetic characterization of ADCs will be performed in order to develop governing design principles for optimal ADC design.